PapersFlow Research Brief
Cancer Treatment and Pharmacology
Research Guide
What is Cancer Treatment and Pharmacology?
Cancer Treatment and Pharmacology is the study and application of pharmacological agents, such as chemotherapy drugs including taxanes, oxaliplatin, and microtubule-targeting agents, to treat cancer while addressing side effects like chemotherapy-induced peripheral neuropathy (CIPN).
This field encompasses 143,409 works focused on chemotherapy-induced peripheral neuropathy in cancer patients, particularly from taxanes and oxaliplatin in breast and colorectal cancer treatments. Key areas include neurotoxic effects, neuroprotective strategies, and impacts on patient quality of life. Microtubule-targeting agents like Eribulin Mesylate are examined for metastatic breast cancer therapy.
Topic Hierarchy
Research Sub-Topics
Chemotherapy-Induced Peripheral Neuropathy
This sub-topic investigates mechanisms, risk factors, and clinical assessment of CIPN from taxanes and platinum agents. Researchers study incidence, severity, and patient-reported outcomes in cancer therapy.
Taxane Neurotoxicity Mechanisms
This sub-topic elucidates microtubule disruption, mitochondrial dysfunction, and axonal degeneration in paclitaxel-induced neuropathy. Researchers explore biomarkers and dose-response relationships.
Oxaliplatin-Induced Neuropathy
This sub-topic covers acute and chronic neuropathy from oxaliplatin, including cold hypersensitivity and sodium channel alterations. Researchers test genetic predictors and symptom management.
Neuroprotective Strategies in Chemotherapy
This sub-topic evaluates pharmacological agents, exercise, and cryotherapy to prevent or ameliorate CIPN. Researchers conduct RCTs on duloxetine, antioxidants, and novel microtubule stabilizers.
Microtubule-Targeting Agents in Oncology
This sub-topic examines stabilizers like eribulin and destabilizers in breast, lung, and sarcoma cancers. Researchers compare efficacy, resistance mechanisms, and combination strategies.
Why It Matters
Cancer Treatment and Pharmacology directly improves patient outcomes through validated regimens, such as bevacizumab added to irinotecan, fluorouracil, and leucovorin, which extended survival in metastatic colorectal cancer patients (Hurwitz et al., 2004, 10,897 citations). Trastuzumab combined with adjuvant chemotherapy reduced recurrence in HER2-positive breast cancer, as shown in trials NCT00004067 and NCT00005970 (Romond et al., 2005, 5,323 citations). Gemcitabine as first-line therapy for advanced pancreatic cancer improved survival and clinical benefit over fluorouracil (Burris et al., 1997, 5,839 citations). These advances, alongside guidelines for evaluating solid tumor responses (Therasse et al., 2000, 15,648 citations), guide clinical practice and funding decisions, like Ontario's FAST program accelerating access to five cancer drugs up to one year earlier.
Reading Guide
Where to Start
'New Guidelines to Evaluate the Response to Treatment in Solid Tumors' by Therasse et al. (2000), as it provides foundational criteria for assessing any cancer treatment efficacy, essential before studying specific drugs.
Key Papers Explained
Therasse et al. (2000) 'New Guidelines to Evaluate the Response to Treatment in Solid Tumors' establishes response criteria used in later trials like Hurwitz et al. (2004) 'Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer', which builds on these by showing bevacizumab's survival benefits; Romond et al. (2005) 'Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer' applies similar metrics to HER2-targeted therapy; Jordan and Wilson (2004) 'Microtubules as a target for anticancer drugs' and Wani et al. (1971) 'Plant antitumor agents. VI. Isolation and structure of taxol' provide mechanistic foundations for taxane pharmacology underpinning these applications.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints highlight trastuzumab deruxtecan's long-term survival benefits in HER2-low metastatic breast cancer from the DESTINY-Breast04 trial (NCT03734029). Work addresses therapy resistance, tumor microenvironment roles, and innovative delivery systems in anti-cancer strategies. Ontario's FAST program fast-tracks funding for high-cost drugs, enabling quicker patient access.
Papers at a Glance
In the News
Five cancer drugs funded quickly through Ontario pilot project
Ontario has expanded public coverage of five cancer treatments more quickly than in the past, thanks to****a pilot project launched last fall to speed up access to oncology breakthroughs.
Province fast-tracks public funding for high-cost cancer drugs
According to the Ontario government, the Funding Accelerated for Specific Treatments (FAST) program is a three‑year pilot that lets the province publicly fund select cancer drugs up to one year ear...
Ontarians will have quicker access to some new cancer ...
The Funding Accelerated for Specific Treatments, or FAST, program aims to connect patients to life-saving and life-changing cancer treatments almost a full year sooner, reducing delays and improvin...
Ontario Connecting Patients to Life-Saving Cancer Drugs Faster
Skip to main content **Newsroom** Search Menu Releases Advisories Bulletins Media Search **Loading...**
From Lab to Patient: The Journey of a Breakthrough ...
The development of a new cancer drug at the University of Alberta shows both the promise and the challenges of drug development. Pacylex Pharmaceuticals, a U of A spinoff, is making incredible stri...
Code & Tools
## About SPARCED SPARCED is a**simple**and**efficient pipeline**for constructing, merging, expanding and simulating**large-scale**, single-cell m...
The cBioPortal for Cancer Genomics provides visualization, analysis, and download of large-scale cancer genomics data sets. For a short intro on cB...
Portable versions provide an**alternative**way to use the tools if for some reason the full installation of the OSP software suite is not practical.
This project successfully combined extensive datasets and advanced machine learning techniques to predict drug sensitivity in cancer cell lines. Th...
Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistanc...
Recent Preprints
Articles | Cancer Chemotherapy and Pharmacology
… 187 Next page
Recent Advances in Anti-Cancer Drugs
Collectively, the papers in this Special Issue address notable gaps in current anti-cancer strategies: resistance to standard therapies, the elusive role of the TME, the need for innovative deliver...
Clinical Cancer Research - AACR Journals
*Clinical Cancer Research*publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of dr...
Articles | Nature Cancer
Show results fromAll journalsThis journal Search Advanced search ### Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician’s choice of chemo...
Latest Developments
Recent developments in cancer treatment and pharmacology research as of February 2026 include significant advancements in cellular therapies such as T-cell therapies, tumor-infiltrating lymphocyte (TIL) therapies, T-cell receptor (TCR) transduced T cells, and smart armored T-cell therapies, which are expected to expand both ex vivo and in vivo (AACR). Additionally, breakthroughs include targeted therapies like menin inhibitors for AML, personalized cancer vaccines, new radiation delivery methods, and tools to better guide treatment decisions (Dana-Farber). Immunotherapy approaches such as Tiragolumab, a TIGIT checkpoint inhibitor, are also showing promising results in clinical trials, especially in combination with PD-1/PD-L1 inhibitors (Frontiers in Pharmacology).
Sources
Frequently Asked Questions
What are standard criteria for evaluating response to cancer treatment?
Therasse et al. (2000) introduced specific criteria in 'New Guidelines to Evaluate the Response to Treatment in Solid Tumors' for measuring tumor shrinkage from anticancer agents, developed by the International Union Against Cancer and World Health Organization. These guidelines standardize assessment of cytotoxic agent activity based on tumor reduction.
How does bevacizumab improve outcomes in metastatic colorectal cancer?
Hurwitz et al. (2004) demonstrated in 'Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer' that adding bevacizumab to fluorouracil-based chemotherapy yields statistically significant survival improvements. This combination provides clinically meaningful benefits for patients.
What is the role of trastuzumab in HER2-positive breast cancer treatment?
Romond et al. (2005) showed in 'Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer' that trastuzumab with paclitaxel after doxorubicin and cyclophosphamide improves outcomes in surgically removed cases. Results from trials NCT00004067 and NCT00005970 confirm reduced recurrence.
How do taxanes function as anticancer drugs?
Jordan and Wilson (2004) explained in 'Microtubules as a target for anticancer drugs' that taxanes like paclitaxel target microtubules to disrupt cancer cell division. Wani et al. (1971) isolated taxol from Taxus brevifolia as a novel antileukemic and antitumor agent in 'Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia'.
What is chemotherapy-induced peripheral neuropathy?
CIPN arises from neurotoxic effects of agents like taxanes and oxaliplatin, impacting quality of life in breast and colorectal cancer patients. The field explores neuroprotective strategies and microtubule-targeting agents like Eribulin Mesylate for metastatic breast cancer.
What survival benefits does gemcitabine offer in pancreatic cancer?
Burris et al. (1997) reported in 'Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial' that gemcitabine enhances survival and reduces tumor-related symptoms compared to prior treatments.
Open Research Questions
- ? How can neuroprotective strategies effectively mitigate CIPN from taxanes and oxaliplatin without reducing chemotherapy efficacy?
- ? What mechanisms underlie resistance to microtubule-targeting agents like Eribulin Mesylate in metastatic breast cancer?
- ? Which combinations of platinum-based drugs with other agents optimize survival in advanced colorectal cancer while minimizing neurotoxicity?
- ? How do tumor microenvironment factors influence responses to trastuzumab deruxtecan in HER2-low breast cancer?
- ? What pharmacogenomic markers predict individual responses to gemcitabine in pancreatic cancer patients?
Recent Trends
Preprints emphasize multi-dimensional oncology approaches tackling resistance, tumor microenvironment, and novel targets, as in 'Recent Advances in Anti-Cancer Drugs'. Trastuzumab deruxtecan shows significant OS and PFS improvements in HER2-low breast cancer (DESTINY-Breast04, 2025).
Ontario's FAST pilot funds five cancer drugs up to one year faster (2026 news), reflecting accelerated clinical translation amid 143,409 works.
Research Cancer Treatment and Pharmacology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cancer Treatment and Pharmacology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers